Every Form 4 that Legend Biotech Corporation (LEGN) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow LEGN and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full LEGN filings page.
Legend Biotech Corp (LEGN) director Corazon (Corsee) D. Sanders sold 27,370 ordinary shares on September 29, 2026, at a weighted average price of $9.4600 per share; individual sale prices ranged from $9.445 to $9.48. The sale was reported as a direct transaction, and no Rule 10b5-1 plan is reported. Sanders held 52,731 ordinary shares following the sale.
Legend Biotech Corp director Peter Salovey received an award of 28,330 restricted share units (RSUs) on September 24, 2026. Each RSU represents a contingent right to receive one ordinary share upon settlement. One-third of the RSUs vest on December 20, 2027; the remainder vest in 12 equal quarterly installments beginning on March 20, 2028, subject to his continued service on each vesting date. His reported direct holding following the transaction was 55,096 ordinary shares.
Legend Biotech Corp (LEGN) director Tomas J. Heyman acquired 20,986 restricted share units (RSUs) on September 24, 2026. Each RSU represents a contingent right to receive one ordinary share upon settlement. His reported direct holdings after the grant were 53,720 ordinary shares. The ordinary shares may be represented by American Depositary Shares (ADSs), with each ADS representing two ordinary shares.
Legend Biotech Corp (LEGN) director Li Mao received an award of 20,986 restricted share units on September 24, 2026. Each RSU represents a contingent right to receive one ordinary share upon settlement. One-third of the RSUs vest on December 20, 2027, with the remainder vesting in 12 equal quarterly installments beginning March 20, 2028, subject to continued service on each vesting date. The reported direct position following the award was 65,316 ordinary shares.
Legend Biotech Corp director Patrick John Casey received an award of 20,986 restricted share units on September 24, 2026. Each RSU represents a contingent right to receive one ordinary share upon settlement. 1/3 of the RSUs will vest on December 20, 2027, with the remainder vesting in 12 equal quarterly installments beginning March 20, 2028, subject to Casey's continued service on each vesting date. His reported direct holdings following the transaction were 69,590 ordinary shares.
Legend Biotech Corp director Darren Xiaohui Ji acquired 28,330 restricted share units (RSUs) on September 24, 2026. Each RSU represents a contingent right to receive one ordinary share upon settlement. One-third of the RSUs will vest on December 20, 2027, with the remainder vesting in 12 equal quarterly installments beginning March 20, 2028, subject to his continued service on each vesting date. His reported direct position following the transaction was 92,103 ordinary shares.
Legend Biotech Corp (LEGN) director Corazon (Corsee) D. Sanders received an award of 20,986 restricted share units (RSUs) on September 24, 2026. Each RSU represents a contingent right to receive one ordinary share. One-third will vest on December 20, 2027, with the remainder vesting in 12 equal quarterly installments beginning March 20, 2028, subject to continued service on each vesting date. Reported direct holdings following the award were 80,101 shares.
Legend Biotech Corp Chief Financial Officer Carlos E. Santos received a grant of 19,676 Ordinary Shares on September 21, 2026. That same day, Santos sold 5,430 Ordinary Shares at a weighted average price of $9.14 per share to satisfy withholding tax obligations upon vesting of restricted share units; sale prices ranged from $8.905 to $9.325 per share. No Rule 10b5-1 plan is reported.
Legend Biotech Corp (symbol: LEGN) is the issuer of record for a Form 4 filing submitted to the SEC. Zhang Ingrid reported acquisition or exercise transactions in this Form 4 filing.
Legend Biotech Corp (LEGN) reported that Chief Executive Officer Ingrid Zhang received an equity award of 1,131,860 restricted share units (RSUs) on September 15, 2026. Each RSU is a contingent right to one ordinary share, vesting in three equal installments on September 15, 2027, 2028, and 2029, subject to continued service.
All 1,131,860 ordinary shares underlying these RSUs are reported as directly owned after the transaction, and the award was granted at a reported price of $0.00 per share. The company notes that its ordinary shares may be represented by ADSs, with each ADS equal to two ordinary shares.
Legend Biotech Corp (LEGN) reported that Interim CEO Alan Bash received a grant of 4,908 restricted share units (RSUs) on August 14, 2026. These RSUs convert into ordinary shares on settlement, increasing his direct holdings to 35,142 ordinary shares. The RSUs vest in three equal annual installments on July 27, 2027, 2028, and 2029, subject to continued service. Each ordinary share may also be represented by American Depositary Shares, with one ADS equal to two ordinary shares.
Legend Biotech Corp director Casey Patrick John sold 6,000 Ordinary Shares in an open-market transaction. The sale took place at $14.80 per ordinary share, equivalent to $29.60 per American Depositary Share, with each ADS representing two ordinary shares. After this trade, he directly holds 48,604 Ordinary Shares, indicating he retains a substantial ongoing equity position in the company.
Legend Biotech Corp director and CEO Ying Huang reported a charitable stock gift. On this Form 4, Huang made a bona fide gift transfer of 3,382 Ordinary Shares of Legend Biotech Corp to a charitable organization, receiving no cash consideration.
After the gift, Huang directly owns 238,490 Ordinary Shares. The company notes that its Ordinary Shares may be represented by American Depositary Shares, with each ADS representing two Ordinary Shares.
Legend Biotech Corp Chief Executive Officer Ying Huang reported a disposition of ordinary shares tied to equity compensation taxes. On June 25, 2026, 5,566 ordinary shares were sold at a weighted average price of $14.78 per share, based on converted ADS prices.
According to the disclosure, these shares were sold to satisfy withholding tax obligations upon the vesting of restricted share units, making this a compensation-related, non-discretionary event rather than a typical open-market sale. Following the transaction, Huang directly holds 241,872 ordinary shares of Legend Biotech.
Legend Biotech Corp Chief Executive Officer Ying Huang reported the sale of 9,936 ordinary shares on March 25, 2026. The weighted average price was $8.77 per ordinary share. According to the disclosure, these shares were sold to satisfy withholding tax obligations upon the vesting of restricted share units. Following this transaction, Huang directly holds 247,438 ordinary shares.